AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$NKTR

Zalevsky Jonathan sold $13K of NKTR

Zalevsky Jonathan (Chief R&D Officer) sold 186 shares of NEKTAR THERAPEUTICS (NKTR) at $71.98 on 2026-08-18.

Original reporting
SEC EDGAR · Zalevsky Jonathan
Published Aug 20, 2026, 11:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NKTR
Neutral
high confidence
Mentioned
$NKTR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NKTRNeutralLow
01

Why it matters

The transaction is a routine insider sale with minimal financial impact.

02

Market read

Low relevance; the disclosed sale is small and unlikely to affect NKTR's stock price.

03

What to watch

Potential upcoming clinical trial updates not reflected in this filing.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑08‑18

Background

Nektar Therapeutics (NKTR) filed a Form 4 reporting a sale of 186 shares by its Chief R&D Officer.

Company-level read

Ticker impact

$NKTRNeutralHigh confidence
Context

Form 4 filing shows Chief R&D Officer sold 186 shares for $13.4K, reducing his stake to 9,570 shares.

Expected impact

No significant impact; price may stay flat.

Evidence & confidence

The sale size is small relative to float and market cap, and no broader context suggests distress.

Market effects

Sector

None; insider activity does not affect biotech sector broadly.

Regional

None; limited to US market.

Global

None

Counterpoint

What could challenge this read

Even small insider sells can signal upcoming negative news; monitor upcoming disclosures.

Key entities

  • Officer
    Zalevsky Jonathan

    Chief R&D Officer of NKTR

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NKTR insider trading history →

Related articles

OCT 8
$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

mondaq.com2 min
OCT 7
$NKTRLow

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.

finance.yahoo.com2 min
OCT 1
$NKTRMedAI 8/10

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Nektar Therapeutics (NKTR) shares fell 21% after reporting modest new response rates for its experimental skin drug, rezpegaldesleukin, in alopecia and eczema studies. Despite this, analysts at William Blair and Jefferies maintained bullish ratings, citing the drug's durability advantage. The company also faces an ongoing legal dispute with Eli Lilly.

newsable.asianetnews.com2 min